Heather Wakelee, MD

The panel discusses treatment considerations for consolidation durvalumab.

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

The panel looks at a second patient case study.

The panel discusses management of resectable early-stage non–small cell lung cancer.

The panel discusses the factors that go into selecting patients for adjuvant therapy.

The panel discusses reassessing for respectability after certain treatments.

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

Recommendations for community hospitals and physicians on the critically necessary molecular tests needed for patients with NSCLC.

Drs Spicer and Sabari explain if and when they test patients with NSCLC for EGFR mutations after surgical resection.

Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.

Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.

Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.

Drs Wakelee, Sabari, and Wistuba review updated data on neoadjuvant treatment in NSCLC from key studies including CheckMate-816 and NADIM-2.

The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.

Ignacio Wistuba, MD, leads the discussion on the role of liquid biopsies for molecular testing in early NSCLC.

Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.

A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses the importance of next-generation sequencing testing in the treatment of patients with non–small cell lung cancer.